UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Why Choose An Index Fund focuses on simplicity, broad exposure, and cost efficiency as strong reasons for a long-term approach.
21,836 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A voluntary recall of thousands of Waymo AVs grabbed headlines, but the bigger story is the decade ahead for autonomo...
So-Young's Q1 2026 results offer clues about growth momentum and profitability. This article breaks down the numbers,...
A potential policy showdown between a president and the Fed chair could ripple through markets. This piece explains t...
Developers race to add native privacy to Ethereum as investors rotate into privacy-first assets. A 12-month deadline ...
In a high-rate environment, Verizon’s steady cash flow and dividend attract institutional buyers. Here’s why it’s gai...
Investors weigh a fresh entry point for ServiceNow as the stock resets after sector-wide multiple compression. Analys...
The Starship launch is drawing global attention, but SpaceX remains private. This guide explains what that means for ...
As Orion (OEC) prepares for 2026 earnings season, this guide breaks down the drivers, cash flow dynamics, and risks t...
Investors are watching Bionano Genomics as the company enters 2026 with evolving demand for optical genome mapping. T...
Big Tech’s AI investments are driving a potential $700B spend this year. This guide breaks down who wins, how to inve...
SpaceX's plan to go public is one of a kind. This article breaks down what it could mean for investors, from the loft...